Aurobindo Pharma Ltd Share Price

Q: What is the share price of Aurobindo Pharma Ltd today?

Aurobindo Pharma Ltd share price as on 31 Jan 2025 is ₹1163.8

Pharmaceuticals - Indian - Bulk Drugs & Formln Lrg

NSE: AUROPHARMA Mid Cap ISIN: INE406A01037

As on 31 January 2025 at 14:09 IST

₹1,163.80

-19.35

(-1.64%)

Sell Buy

About Aurobindo Pharma Ltd

Aurobindo Pharma Limited is a major Indian pharmaceutical company. It has established itself as a key player in the global healthcare industry since its inception in 1986. The company's headquarters are in HITEC City, Hyderabad. Its extensive product portfolio includes antibiotics, antiretrovirals, cardiovascular products and anti-diabetics. Aurobindo Pharma has established a strong global presence, with its products being sold in over countless countries. This international reach has positioned the company as one of India's largest pharmaceutical firms. The Reddy family maintains a substantial promoter shareholding, providing strong backing for its operations. Read More...

Over 1 Month

-8.87%

Over 6 Months

-15.46%

Over 1 Year

2.34%

Over 3 Years

86.48%

Aurobindo Pharma Ltd Summary

Close ₹ 1,163.80

Open ₹ 1,180.10

High ₹ 1,189.45

Low ₹ 1,162.10

Volume 5,84,967

Net Turnover (in ₹ Cr) ₹ 121.17

52Wk High ₹ 1,592

52Wk Low ₹ 958.50

52Wk High / Low

958.50

1,592

Aurobindo Pharma Ltd Fundamentals

Key Financial Data

Market Cap (in ₹Cr) ₹ 69,325.33

EPS (TTM) 35.31

Book Value (BV) 335.47

Div. Yield 0.38 %

P/E (TTM) 33.48

Price/Book Value 3.52

Delivery % 27.07 %

Face Value 1

Key Ratios

PE Ratio 32.67

PB Ratio 3.24

EV to Sales 6.26

PEG Ratio 0.55

ROA 8.64

ROE 10.35

Debt-Equity 0.19

Net Profit Margin 18.36

Operating Profit Margin 27.19

Aurobindo Pharma Ltd Financials

Profit and Loss

Consolidated

Standalone

Yearly

Quarterly

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	29,559.25	25,145.97	23,775.84	25,155.47	23,290.38
Total Expenses	24,970.24	22,521.80	20,243.88	20,571.10	19,506.04
Profit Before Tax	4,379.99	2,612.50	3,372.74	7,343.59	3,743.04
Profit After Tax	3,168.97	1,927.65	2,647.11	5,333.82	2,843.69
Operating Profit after Depreciation	4,878.72	2,764.65	3,580.60	4,658.86	4,089.47

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	15,622.12	11,917.30	11,341.73	10,006.22	9,760.59
Total Non Current Assets	21,299.59	18,430.08	15,799.03	14,030.48	12,515.23
Total Current Assets	23,771.92	21,459.91	18,122.69	19,823.51	16,412.51
TOTAL ASSETS	45,071.51	39,889.99	33,921.72	33,853.99	28,927.74
Total Shareholder's Fund	29,842.80	26,839.85	24,575.98	21,929.87	16,824.67

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	2,434.52	2,386.75	5,016.48	3,329.05	4,381.28
Net Cash used in Investing Activities	-4,241.78	-3,971.40	-3,211.36	596.57	-1,562.86
Net Cash used in Financing Activities	800.42	1,814.41	-2,969.27	-1,364.94	-1,947.18

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	11,261.70	8,900.92	11,958.13	16,413.54	13,759.56
Total Expenses	8,858.78	7,269.93	10,245.94	12,220.53	11,389.51
Profit Before Tax	2,402.92	1,630.99	1,637.48	4,193.01	2,370.05
Profit After Tax	1,900.10	1,242.17	1,454.71	3,112.91	1,876.88
Operating Profit after Depreciation	2,585.52	1,705.57	1,729.13	4,221.69	2,613.33

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	2,419.13	3,687.50	3,585.83	4,487.94	4,417.80
Total Non Current Assets	17,914.85	15,093.82	11,765.84	10,852.98	8,275.31
Total Current Assets	7,239.13	9,964.99	9,835.11	12,336.01	11,288.30
TOTAL ASSETS	25,153.98	25,058.81	21,600.95	23,188.99	19,563.61
Total Shareholder's Fund	19,722.82	18,034.03	17,117.34	15,924.61	13,052.50

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	1,714.80	1,816.17	3,726.71	2,994.53	2,201.38
Net Cash used in Investing Activities	-151.58	-3,229.65	-1,614.54	-2,650.24	-948.08
Net Cash used in Financing Activities	-1,837.03	1,719.48	-2,447.54	-28.06	-1,254.65

Particulars (in ₹ Cr.)	2024-09	2024-06	2024-03	2023-12	2023-09
Total Revenue	7,796.07	7,567.02	7,580.15	7,351.78	7,219.42
Total Expenses	6,229.93	5,948.84	5,920	5,753.06	5,845.98
Profit Before Tax	1,207.46	1,323.89	1,229.90	1,262.42	1,075.64
Profit After Tax	816.95	918.22	907.35	939.97	751.94
Operating Profit after Depreciation	1,702.44	1,839.11	1,795.77	1,761.24	1,561.32

Particulars (in ₹ Cr.)	2024-09	2024-06	2024-03	2023-12	2023-09
Total Revenue	2,824.59	2,460.09	2,894.03	2,692.03	2,668.76
Total Expenses	2,103.71	1,961.16	2,119.24	2,210.34	2,123.58
Profit Before Tax	723.75	446.24	779.88	687.22	545.87
Profit After Tax	537.53	329.04	578.67	623.78	415.74
Operating Profit after Depreciation	843.54	564.25	897.76	812.82	648.35

Aurobindo Pharma Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 1,164.05

S2 1,144.95

S3 1,130.30

Pivot 1,178.70

R1 1,197.80

R2 1,212.45

R3 1,231.55

Moving Average

20 SMA 1,208.47

50 SMA 1,235.59

100 SMA 1,339.92

200 SMA 1,320.58

Aurobindo Pharma Ltd Corporate Actions

Dividend

Bonus

Splits

Rights

AGM

EGM

Aurobindo Pharma Ltd

₹1.5/Share

Announcement Date 20 Feb 2024

Record Date 20 Feb 2024

Div Yield 150%

AGM Date: 02 Aug 2022

AGM 02/08/2022 Source : Business Standard Date : 11.07.2022 Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the copies of the Notice published in the newspapers, Business Standard and Nava Telangana on 08.07.2022, intimating the shareholders that the 35th Annual General Meeting of the Company will be held on Tuesday, August 2, 2022 at 3.30 PM (1ST) through Video Conferencing / Other Audio Visual Means. Pursuant to Section 91 of the Companies Act, 2013 and Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Register of Members and Share Transfer Books will remain closed from Friday, July 29, 2022 to Tuesday, August 2, 2022 (both days inclusive). (As Per BSE Announcement dated on 08.07.2022) In continuation to our letter dated July 7, 2022, the 35th Annual General Meeting (AGM) of the Company was held on August 2, 2022 and the business mentioned in the AGM Notice dated June 17, 2022 was transacted. In this regard, please find enclosed the following: 1. Summary of proceedings as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as Annexure- I. 2. Voting Results as required under Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as Annexure-II. 3. The Report of Scrutinizer on remote e-voting and voting at AGM (by electronic means) as Annexure- III. Aurobindo Pharma Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. (As Per BSE Announcement dated on 03.08.2022)

AGM Date: 25 Aug 2023

AGM 25/08/2023 36th AGM of the Company will be held on August 25, 2023 at 3.30 PM. The Register of members and share transfer books will be closed from August 23, 2023 to August 25, 2023 for the purpose of 36th Annual General Meeting to be held on August 25, 2023. (As Per BSE Announcement dated on 28.07.2023) Please find attached the notice published in the newspapers. (As Per BSE Announcement Dated on 02.08.2023) Proceedings of 36th Annual General Meeting of the Company held on August 25, 2023. (As per BSE Announcement Dated on 25/08/2023) Please find enclosed voting results of 36 Annual General Meeting of the Company held on August 25, 2023 and scrutinizer''s report. (As per BSE Announcement Dated on 28/08/2023)

AGM Date: 29 Aug 2024

Intimation of holding of 37th Annual General Meeting of the Company on Thursday, August, 29, 2024. Submission of proceedings of 37th Annual General meeting of the Company held on August 29, 2024. (As Per BSE Announcement dated on 29.08.2024)

Aurobindo Pharma Ltd Peer Comparison

Company	Price	Market Cap (in ₹ Cr)
Aurobindo Pharma Ltd	₹1,182.35	₹69,278.45
Sun Pharmaceuticals Industries Ltd	₹1,745.25	₹4,18,743.94
Divis Laboratories Ltd	₹5,733.60	₹1,52,209.07
Cipla Ltd	₹1,458.15	₹1,17,762.24
Torrent Pharmaceuticals Ltd	₹3,357.15	₹1,13,616.11
Mankind Pharma Ltd	₹2,488.40	₹1,02,663.15

Aurobindo Pharma Ltd News

Apitoria Pharma's Unit 2 completes USFDA inspection

28 Jan 2025, 12:15 pm

Aurobindo Pharma Ltd rises for third straight session

Aurobindo Pharma Ltd is quoting at Rs 1197.8, up 1.65% on the day as on 12:49 IST on the NSE. The stock is up 5.66% in last one year as compared to a 9.94% jump in NIFTY and a 26.31% jump in the Nifty Pharma index.

20 Jan 2025, 01:06 pm

Aurobindo Pharma to table results

On 6 February 2025

17 Jan 2025, 06:01 pm

Aurobindo Pharma Ltd slips for fifth straight session

Aurobindo Pharma Ltd is quoting at Rs 1264, down 2.58% on the day as on 13:19 IST on the NSE. The stock jumped 12.9% in last one year as compared to a 9.26% rally in NIFTY and a 32.39% spurt in the Nifty Pharma index.

08 Jan 2025, 01:35 pm

Aurobindo Pharma Ltd up for third straight session

Aurobindo Pharma Ltd is quoting at Rs 1336.4, up 2.93% on the day as on 12:49 IST on the NSE. The stock is up 23.72% in last one year as compared to a 8.53% jump in NIFTY and a 39.09% jump in the Nifty Pharma index.

31 Dec 2024, 01:05 pm

Aurobindo Pharma Ltd Stock Analysis

Annual revenue for Aurobindo Pharma Ltd increased by 26.52% to ₹11,261.70 crore in FY 2024 from ₹8,900.92 crore in FY 2023.
Annual Net Profit for Aurobindo Pharma Ltd increased by 52.97% to ₹1,900.10 crore in FY 2024 from ₹1,242.17 crore in FY 2023.
Promoter Shareholding in Aurobindo Pharma Ltd remains unchanged by 0.00% in the most recent quarter, from 51.82% in September 2024 to 51.82% in December 2024.
Aurobindo Pharma Ltd delivered a 1-year return of 2.34% compared to the Nifty 50, which provided a return of 8.03% as of the last trading session.
Aurobindo Pharma Ltd share price moved down by 1.64% from its previous close of INR ₹1,183.15. The latest Aurobindo Pharma Ltd share price is INR ₹1,163.80.
Aurobindo Pharma Ltd share price today has been at a low of 1,162.10 and a high of 1,189.45. Over the past 52 weeks, the Aurobindo Pharma Ltd share price has seen a low of 958.50 and a high of 1,592.

About Aurobindo Pharma Ltd

Aurobindo Pharma Limited is a major Indian pharmaceutical company. It has established itself as a key player in the global healthcare industry since its inception in 1986. The company's headquarters are in HITEC City in Hyderabad.

Aurobindo Pharma was founded by P.V. Ramprasad Reddy and K. Nityananda Reddy, who remain the primary promoters. The company’s extensive product portfolio includes antibiotics, antiretrovirals, cardiovascular products and anti-diabetics. Aurobindo Pharma has established a strong global presence, with its products being sold in over 150 countries. This international reach has positioned the company as one of India's largest pharmaceutical firms.

It is not currently the top-ranked stock in its sector. However, Aurobindo Pharma is a significant force in the generic pharmaceuticals market. The company’s registered office is located in Maitri Vihar, Ameerpet, Hyderabad. Meanwhile, the registrar’s office is in the Financial District. The company is led by Managing Director K Nithyananda Reddy.
Apart from him, there are a lot of managerial promoters who have contributed to the success of the company. They are M Madan Mohan Reddy, Satakarni Makkapati, Girish P Vanvari, Santanu Mukherjee and Deepali Pant Joshi.

The Reddy family maintains a substantial promoter shareholding in the company, providing strong backing for its operations. Aurobindo Pharma’s success can be attributed to its experience and commitment to quality. As a result, Aurobindo Pharma continues to play a crucial role in providing accessible healthcare solutions worldwide. Its diverse range of products and strong market presence underscore its importance in the global pharmaceutical landscape.

How Aurobindo Pharma Is Reshaping Access to Medicine

Aurobindo Pharma is making significant contributions to improving access to medicine. The company focuses on producing affordable generic medicines, which helps reduce healthcare costs. This makes essential drugs more accessible to a broader population.

One of Aurobindo Pharma’s key strategies is the rapid introduction of generic versions of drugs as soon as patents expire. This “Day-1 generic policy” ensures that patients have access to affordable alternatives without delay. Aurobindo Pharma helps lower the overall cost of medications. This is crucial for patients in low and middle-income countries.

Aurobindo Pharma also works on expanding its product portfolio to include a wide range of therapeutic areas. The company manufactures antibiotics and central nervous system medications, among others. This ensures that patients have access to treatments for different health conditions.

In addition to its product range, Aurobindo Pharma is committed to maintaining high standards of quality and safety. The company adheres to stringent regulatory requirements. It has also received approvals from major health authorities, including the US FDA and the European Medicines Agency. This commitment to quality ensures that patients receive safe and effective medications.

Aurobindo Pharma’s efforts extend beyond just manufacturing and distributing medicines. The company is also involved in initiatives to improve healthcare infrastructure and education. For example, Aurobindo Pharma collaborates with various organisations to support healthcare programs. These initiatives help strengthen the overall healthcare system and improve patient outcomes.

Moreover, Aurobindo Pharma is actively working to address the issue of antimicrobial resistance (AMR). The company has implemented measures to ensure responsible manufacturing practices. This has reduced the environmental impact of antibiotic production. As a result, Aurobindo Pharma contributes to global efforts to combat AMR.

Aurobindo Pharma’s commitment to accessibility is also evident in its efforts to reach underserved markets. The company has expanded its presence in Africa and Asia, where access to affordable medicines is often limited. It has increased the availability of its products in these regions. As a result, Aurobindo Pharma helps bridge the gap in healthcare access and improve the quality of life for many patients.

Aurobindo Pharma’s approach to reshaping access to medicine is multifaceted. The company not only focuses on affordability but also on ensuring the quality and safety of its products. This dual focus is essential in providing reliable healthcare solutions to patients worldwide.
Aurobindo Pharma collaborates with various organisations, including non-profits and the government. This is to enhance its impact on global health. These partnerships enable the company to participate in large-scale health initiatives. Aurobindo Pharma also works together with other stakeholders. This allows the company to leverage their expertise and resources to achieve broader health outcomes.

Looking ahead, Aurobindo Pharma aims to continue expanding its global footprint. The company plans to enter new markets and introduce innovative treatments. With a strong focus on affordability, Aurobindo Pharma is well-positioned to make a lasting impact on global health. Aurobindo Pharma actively engages with the communities where it operates. The company supports various social initiatives, including education and infrastructure development. As a result, it contributes to the overall well-being of society.

Aurobindo Pharma’s approach to reshaping access to medicine encompasses affordability and quality. It also focuses on sustainability and education. The company’s initiatives are making a major impact on global health, ensuring that more people have access to the medicines they need. Through its continued efforts, Aurobindo Pharma is helping to create a healthier, more equitable world.